Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 4/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483662 | 1.00 | FFAR2 (0.48) | FFAR2S1PR5KCNH2MAOBKDM4E | |
| SCHEMBL12079896 | 0.85 | KCNH2 (0.66) | FFAR2KCNH2MAOBNPC1 | |
| SCHEMBL311548 | 0.85 | KCNH2 (0.59) | FFAR2S1PR5KCNH2MAOBKDM4E | |
| SCHEMBL310922 | 0.85 | KCNH2 (0.59) | FFAR2S1PR5KCNH2MAOBKDM4E | |
| SCHEMBL310672 | 0.85 | KCNH2 (0.59) | FFAR2S1PR5KCNH2MAOBKDM4E | |
| SCHEMBL483621 | 0.85 | KCNH2 (0.59) | FFAR2S1PR5KCNH2MAOBKDM4E | |
| SCHEMBL28498715 | 0.84 | FFAR2 (0.45) | FFAR2S1PR5KCNH2MAOBKDM4E | |
| SCHEMBL26999842 | 0.83 | RIPK1 (0.46) | FFAR2SMN1; SMN2NPSR1 | |
| SCHEMBL2837206 | 0.83 | FFAR2 (0.54) | FFAR2S1PR5KCNH2MAOBNR4A1 | |
| SCHEMBL2835415 | 0.83 | FFAR2 (0.54) | FFAR2S1PR5KCNH2MAOBNR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153623-B2 | Compounds | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153681-B2 | Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8143306-B2 | Methods of treating bipolar disorders | Convergence Pharmaceuticals Limited (GB) | 2012-03-27 | — | — | US | disclosed |
| EP-1934176-B1 | QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | GLAXO GROUP LTD (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-20110098335-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098335-A1 | NOVEL COMPOUNDS | SCN1A, SCN1B, SCNN1B | FFAR2 459/4885S1PR5 359/4885KCNH2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.